KUTANÖZ SARKOİDOZ

Bahar Sevimli Dikicier

KUTANÖZ SARKOİDOZ

Öz

Sarkoidoz kronik, inflamatuar, multisistemik, granülom oluşumuyla karakterize bir hastalıktır. Akciğerlerden sonra en sık etkilenen organ deridir. Deride sarkoidoz çok çeşitli klinik görünümlerle ortaya çıkabilir. Bu derlemede sarkoidozun deri tutulumuna ait güncel epidemiyolojik, klinik, histopatolojik bilgiler ve tedavi seçenekleri anlatılmaktadır.

Anahtar Kelimeler

deri,kutanöz,sarkoidoz

References

1. Mañá J, Marcoval J, Rubio M, et al. Granulomatous cutaneous sarcoidosis: diagnosis, relationship to systemic disease, prognosis and treatment. Sarcoidosis Vasc Diffuse Lung Dis 2013; 30: 268-81.
2. Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med 2007; 357: 2153-65.
3. Ungprasert P, Wetter DA, Crowson CS, et al. Epidemiology of cutaneous sarcoidosis 1976-2013: a population-based study from Olmsted County, Minnesota. J Eur Acad Dermatol Venereol 2016; 30: 1799-1804.
4. TongC, ZhangX, DongJ, et al. Comparison of cutaneous sarcoidosis with systemic sarcoidosis: a retrospective analysis. Int J Clin Exp Pathol 2014; 7: 372-77.
5. Ishak R, Kurban M, Kibbi AG, et al. Cutaneous sarcoidosis: clinicopathologic study of 76 patients from Lebanon. Int J Dermatol 2015; 54: 33–41.
6. Esteves TC, Aparicio G, Ferrer B, et al. Prognostic value of skin lesions in sarcoidosis: clinical and histopathological clues. Eur J Dermatol 2015; 25: 556-62.
7. Brito-Zeron P, Sellares J, Bosch X, et al. Epidemiologic patterns of disease expression in sarcoidosis: age, gender and ethnicity-related differences. Clin Exp Rheumatol 2016; 34: 380-8.
8. Carrillo-Perez DL, Apodaca-Chaveza EI, Carrillo-Maravilla E, et al. Sarcoidosis: a single hospital-based study in a 24-year period. Revista de Investigacion Clinica 2015; 67: 33-8.

9. Marchell MR, Thiers B, Judson MA. Sarcoidosis. In: Wolff K, Goldsmith L, Katz S, Gilchrest B, Paller AS, Leffell D, Amy Paller, editors. Fitzpatrick's Dermatology in General Medicine, 7th Edition. New York: McGraw-Hill, 2008; p. 1485-1492.
10. Nakamura S, Hashimoto Y, Nishi K, et al. High rate of cardiac sarcoidosis presenting with cutaneous plaque type sarcoidosis in 18F-fluorodeoxyglucose positron emission tomography-computed tomography: a case series. J Med Case Rep 2014; 8: 17.
11. Marcoval J, Mana J, Moreno A, Peyri J. Subcutaneous sarcoidosis: clinico pathological study of 10 cases. Br J Dermatol 2005; 153: 790-94.
12. Marcoval J, Mana J. Papular sarcoidosis of the knees. A frequent form of presentation of systemic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2016; 33: 59-65.
13. Judson MACU, Drent M, Wells A, et al. The WASOG sarcoidosis organ assessment instrument: an update of a previous clinical tool. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31: 19-27.
14. Ando M, Miyazaki E, Hatano Y, et al. Subcutaneous sarcoidosis: a clinical analysis of nine patients. Clin Rheumatol 2016; 35: 2277-81.
15. Dulguerov N, Vankatova L, Landis BN. Subcutaneous sarcoidosis in a rhinoplasty scar. BMJ Case Rep 2015.
16. Zargham H, O’Brien E. Cutaneous sarcoidosis at insulin injection sites. CMAJ 2016; 188: 674.
17. Marcoval J, Fanlo M, Penin RM, et al. Systemic sarcoidosis with specific cutaneous lesions located at insulin injection sites for diabetes mellitus. J Eur Acad Dermatol Venereol 2014; 28: 1259-60.
18. Mermin D, Loustalan MP, Doutre MS. A case of hyaluronic acid injections triggering cutaneous sarcoidosis at previously treated sites. J Eur Acad Dermatol Venereol 2017; 31:e55 -7.
19. Herbert VG, Blodorn-Schlicht N, Boer-Auer A, et al. Cutaneous granulomatous reactions at botulinum neurotoxin A injection sites: first manifestation of systemic sarcoidosis. Hautarzt 2015; 66: 863-6.
20. Morand M, Beauregard S, Mathieu S. Systemic sarcoidosis revealed by axillary electrolysis. J Cutan Med Surg 2015; 19: 404-6.
21. Serup J, Sepehri M, Hutton Carlsen K. Classification of tattoo complications in a hospital material of 493 adverse events. Dermatology 2016; 232: 668-78.
22. Pereira IB, Khan A. Sarcoidosis rare cutaneous manifestations: vulval and perianal involvement. J Obstetr Gynaecol 2017; 37: 539-540.
23. Dan L, Relic J. Sarcoidosis presenting as nonscarring nonscalp alopecia. Aust J Dermatol 2016; 57: e112 -3.
24. Madureira P, Pimenta S, Cardoso H, et al. Sarcoidosis: an unusual presentation. Reumatologia Clinica 2017; 13: 227-9.
25. Infusino SD, Ismaili A, Passarini B. Cutaneous sarcoidosis with zosteriform distribution and pulmonary involvement. Giornale Italiano di Dermatologia Venereologia 2016; 151: 315-6.
26. Vatanchi M, Sobhani K, Fisher VT, et al. Cutaneous sarcoidosis masquerading as chronic cutaneous lupus erythematosus: case report. BMC Dermatol 2016; 16: 14. 27. Miura T, Kato Y, Yamamoto T. Ichthyosiform sarcoidosis: report of three cases from Japan and literature review. Sarcoidosis Vasc Diffuse Lung Dis 2016; 33: 392-7.
28. Vega ML, Abrahams J, Keller M. Psoriasiform sarcoidosis: collision of two entities or expression of one common pathogenesis? J Clin Aesthet Dermatol 2016; 9: 55-7.
29. Wollina U, Baunacke A, Hansel G. Multisystemic sarcoidosis presenting as pretibial leg ulcers. Int J Low Extrem Wounds 2016; 15: 263-6.
30. Barisani A, Negosanti M, La Placa M, et al. Erythematous patches and pretibial ulcers: an uncommon presentation of cutaneous sarcoidosis. Journal der Deutschen Dermatologischen Gesellschaft 2016; 14: 295-7.
31. Martinez Leborans L, Esteve Martinez A, Victoria Martinez AM, et al. Cutaneous sarcoidosis in a melanoma patient under Ipilimumab therapy. Dermatol Therapy 2016; 29: 306-8.
32. Cotliar J, Querfeld C, Boswell WJ, et al. Pembrolizumab-associated sarcoidosis. JAAD Case Rep 2016; 2: 290-93.
33. Naidoo J, Schindler K, Querfeld C, et al. Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1. Cancer Immunol Res 2016; 4: 383-89.
34. Lau KH, Kumar A, Yang IH, et al. Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab. Muscle Nerve 2016; 54: 157-61.
35. Lheure C, Kramkimel N, Franck N, et al. Sarcoidosis in patients treated with vemurafenib for metastatic melanoma: a paradoxical autoimmune activation. Dermatology 2015; 231: 378 -84.
36. Vieira MA, Saraiva MI, Silva LK, et al. Development of exclusively cutaneous sarcoidosis in patient with rheumatoid arthritis during treatment with etanercept. Revista da Associacao Medica Brasileira 2016; 62: 718-20.
37. Numakura T, Tamada T, Nara M, et al. Simultaneous development of sarcoi- dosis and cutaneous vasculitis in a patient with refractory Crohn’s disease during infliximab therapy. BMC Pulm Med 2016; 16: 30.
38. Park SK, Hwang PH, Yun SK, et al. Tumor necrosis factor alpha blocker- induced erythrodermic sarcoidosis in with juvenile rheumatoid arthritis: a case report and review of the literature. Ann Dermatol 2017; 29: 74 -8.
39. Waltschew A. Cutaneous sarcoidosis after treatment with interferon for hepatitis C: a not entirely rare but often overlooked reaction. Der Pathologe 2016; 37: 184-6.
40. Gargallo V, Ramos F G, Rodriguez-Peralto F L, et al. Sarcoidosis and cutaneous lymphoma: what is the relationship? Ann Brasil Dermatol 2017; 92: 158-9.
41. Berg SA, Novoa RA, Stewart C, et al. Sarcoidosis and squamous cell carcinoma: a connection documented in a case series of 3 patients. Cutis 2016; 98: 377-80.
42. Westers-Attema A, Abdul Hamid M, Haans E, et al. Multiple cutaneous squamous cell carcinoma in cutaneous sarcoidosis. J Dermatol 2015; 42: 845-46.
43. Karmakar S, Ramesh V. Cutaneous sarcoidosis and macular amyloidosis occurring at the same site. Indian J Dermatol Venereol Leprol 2016; 82: 574-76.
44. Baughman RP, Judson MA, Teirstein A, et al. Chronic facial sarcoidosis including lupus pernio: clinical description and proposed scoring systems. Am J Clin Dermatol 2008; 9: 155-61.
45. Yeung H, Farber S, Birnbaum BK, et al. Reliability and validity of cutaneous sarcoidosis outcome instruments among dermatologists, pulmonologists, and rheumatologists. JAMA Dermatol 2015; 151: 1317-22.
46. Ramadan S, Hossam D, Saleh MA. Dermoscopy could be useful in differentiating sarcoidosis from necrobiotic granulomas even after treatment with systemic steroids. Dermatol Pract Concept 2016; 6: 17-22.
47. Tada S, Watanabe T, Suzuki C, et al. Sonographic findings of subcutaneous sarcoidosis in 3 cases. J Ultrasound Med 2015; 34: 1485-88.
48. Dybiec E, Pietrzak A, Bartosinska J, et al. Ultrasound findings in cutaneous & sarcoidosis. Postepy Dermatol Alergol 2015; 32: 51-5.
49. Jones E, Callen JP. Hydroxychloroquine is effective therapy for control of cutaneous sarcoidal granulomas. J Am Acad Dermatol 1990; 23: 487-89.
50. Marchetti M, Baker MG, Noland MM. Treatment of subcutaneous sarcoidosis with hydroxychloroquine: report of 2 cases. Dermatol Online J 2014; 20: 21250.
51. Modi S, Rosen T. Micropapular cutaneous sarcoidosis: case series successfully managed with hydroxychloroquine sulfate. Cutis 2008; 81: 351-54.
52. Zic JA, Horowitz DH, Arzubiaga C, et al. Treatment of cutaneous sarcoidosis with chloroquine. Review of the literature. Arch Dermatol 1991;127: 1034-40.
53. Khatri KA, Chotzen VA, Burrall BA. Lupus pernio: successful treatment with a potent topical corticosteroid. Arch Dermatol 1995;131: 617-18.
54. Wise RD. Clinical resolution of facial cutaneous sarcoidosis with systemic colchicine and a topical corticosteroid ointment. Compr Ther 2008; 34: 105–110.
55. Singh SK, Singh S, Pandey SS. Cutaneous sarcoidosis without systemic involvement: response to intralesional corticosteroid. Indian J Dermatol Venereol Leprol 1996; 62: 273-74.
56. Wanat KA, Rosenbach M. Cutaneous Sarcoidosis. .Clin Chest Med 2015; 36: 685-702.
57. Gharavi N, Diehl J, Soriano T. Cutaneous sarcoidosis successfully treated with intralesional 5-fluorouracil. Dermatol Surg 2015; 41: 1082-85.
58. Abbott J, Taylor LA, Wanat KA, et al. Isolated subcutaneous sarcoid-like granulomatous inflammation occurring at injection sites: 3 patients treated successfully with minocycline. JAAD Case Rep 2017; 3: 74 -77.
59. Zabel P, Entzian P, Dalhoff K, et al. Pentoxifylline in treatment of sarcoidosis. Am J Respir Crit Care Med 1997; 155: 1665-669.
60.Baughman RP, Judson MA, Ingledue R, et al. Efficacy and safety of apremilast in chronic cutaneous sarcoidosis. Arch Dermatol 2012; 148: 262-64.
61. Georgiou S, Monastirli A, Pasmatzi E, et al. Cutaneous sarcoidosis: complete remission after oral isotretinoin therapy. Acta Derm Venereol 1998; 78: 457-59.
62. Veien NK, Brodthagen H. Cutaneous sarcoidosis treated with methotrexate. Br J Dermatol 1977; 97: 213-16.
63. Vorselaars AD, Wuyts WA, Vorselaars VM, et al. Methotrexate vs azathioprine in second-line therapy of sarcoidosis. Chest 2013;144: 805-12.
64. Webster GF, Razsi LK, Sanchez M, et al. Weekly low-dose methotrexate therapy for cutaneous sarcoidosis. J Am Acad Dermatol 1991; 24: 451-54.
65. Webster GF, Razsi LK, Sanchez M, et al. Methotrexate therapy in cutaneous sarcoidosis. Ann Intern Med 1989; 111: 538-39.
66. Field S, Regan AO, Sheahan K, et al. Recalcitrant cutaneous sarcoidosis responding to adalimumab but not to etanercept. Clin Exp Dermatol 2010; 35: 795-96.
67. Heffernan MP, Smith DI. Adalimumab for treatment of cutaneous sarcoidosis. Arch Dermatol 2006; 142: 17-19.
68. Pariser RJ, Paul J, Hirano S, et al. A double-blind, randomized, placebo-controlled trial of adalimu- mab in the treatment of cutaneous sarcoidosis. J Am Acad Dermatol 2013; 68: 765-73.
69. Philips MA, Lynch J, Azmi FH. Ulcerative cutaneous sarcoidosis responding to adalimumab. J Am Acad Dermatol 2005; 53: 917.
70. Heffernan MP, Anadkat MJ. Recalcitrant cutaneous sarcoidosis responding to infliximab. Arch Derm tol 2005; 141: 910-11.
71. Meyerle JH, Shorr A. The use of infliximab in cutaneous sarcoidosis. J Drugs Dermatol 2003; 2: 413-14.
72. Sene T, Juillard C, Rybojad M, et al. Infliximab as a steroid-sparing agent in refractory cutaneous sarcoidosis: single-center retrospective study of 9 patients. J Am Acad Dermatol 2012; 66: 328-32.
73. Tu J, Chan J. Cutaneous sarcoidosis and infliximab: evidence for efficacy in refractory disease. Australas J Dermatol 2013; 55: 279-81.
74. Tuchinda P, Bremmer M, Gaspari AA. A case series of refractory cutaneous sarcoidosis successfully treated with infliximab. Dermatol Ther 2012; 2:11.
75. Wanat KA, Rosenbach M. Case series demonstrating improvement in chronic cutaneous sarcoidosis following treatment with TNF inhibitors. Arch Dermatol 2012; 148: 1097-2000.
76. Utz JP, Limper AH, Kalra S, et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 2003; 124: 177-85.
77. Thielen AM, Barde C, Saurat JH, et al. Refractory chronic cutaneous sarcoidosis responsive to dose escalation of TNF-alpha antagonists. Dermatology 2009; 219: 59–62.
78. Dhaille F, Viseux V, Caudron A, et al. Cutaneous sarcoidosis occurring during anti-TNF-alpha treatment: report of two cases. Dermatology 2010; 220: 234-37.
79. Tong D, Manolios N, Howe G, et al. New onset sarcoid-like granulomatosis developing during anti-TNF therapy: an underrecognised complication. Intern Med J 2012; 42: 89-94.
80. Santos G, Sousa LE, Joao AM. Exacerbation of recalcitrant cutaneous sarcoidosis with adalimumab - a paradoxical effect? A case report. An Bras Dermatol 2013; 88: 26-28.
81. Fok KC, Ng WW, Henderson CJ, et al. Cutaneous sarcoidosis in a patient with ulcerative colitis on infliximab. J Crohns Colitis 2012; 6: 708-12.
82. Karrer S, Abels C, Wimmershoff MB, et al. Successful treatment of cutaneous sarcoidosis using topical photodynamic therapy. Arch Dermatol 2002; 138: 581-84.
83. Penrose C, Mercer SE, Shim-Chang H. Photodynamic therapy for the treatment of cutaneous sarcoidosis. J Am Acad Dermatol 2011; 65:e12-4.
84. Wilsmann-Theis D, Bieber T, Novak N. Photodynamic therapy as an alternative treatment for cutaneous sarcoidosis. Dermatology 2008; 217: 343-46.
85. Mahnke N, Medve-Koenigs K, Berneburg M, et al. Cutaneous sarcoidosis treated with medium-dose UVA1. J Am Acad Dermatol 2004; 50: 978-79.
86.Ginoux E, Kottler D, Anglaret B, et al. Remission of a long-lasting sarcoidosis after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia. JAAD Case Rep 2016; 2: 408-10.
87.Kushima H, Ishii H, Ikewaki J, et al. Sarcoidosis in donor-derived tissues after haematopoietic stem cell transplantation. Eur Respir J 2013; 41: 1452-53.
88. Emer J, Uslu U, Waldorf H. Improvement in lupus pernio with the successive use of pulsed dye laser and nonablative fractional resurfacing. Dermatol Surg 2014; 40: 201-02.
89. Noe MH, Rosenbach M. Cutaneous sarcoidosis. Curr Opin Pulm Med 2017; 23: 482-86.

Details

Primary Language

Turkish

Subjects

-

Journal Section

Review

Authors

Bahar Sevimli Dikicier This is me

Publication Date

April 6, 2018

Submission Date

March 6, 2018

Acceptance Date

March 30, 2018

Published in Issue

Year 1970 Volume: 3 Number: 1

IZ

https://izlik.org/JA99BN93PN

Cite

RIS / Bibtex

APA

Sevimli Dikicier, B. (2018). KUTANÖZ SARKOİDOZ. Güncel Dermatoloji Dergisi, 3(1), 33-43. https://izlik.org/JA99BN93PN

AMA

1.Sevimli Dikicier B. KUTANÖZ SARKOİDOZ. GDD. 2018;3(1):33-43. https://izlik.org/JA99BN93PN

Chicago

Sevimli Dikicier, Bahar. 2018. “KUTANÖZ SARKOİDOZ”. Güncel Dermatoloji Dergisi 3 (1): 33-43. https://izlik.org/JA99BN93PN.

EndNote

Sevimli Dikicier B (April 1, 2018) KUTANÖZ SARKOİDOZ. Güncel Dermatoloji Dergisi 3 1 33–43.

IEEE

[1]B. Sevimli Dikicier, “KUTANÖZ SARKOİDOZ”, GDD, vol. 3, no. 1, pp. 33–43, Apr. 2018, [Online]. Available: https://izlik.org/JA99BN93PN

ISNAD

Sevimli Dikicier, Bahar. “KUTANÖZ SARKOİDOZ”. Güncel Dermatoloji Dergisi 3/1 (April 1, 2018): 33-43. https://izlik.org/JA99BN93PN.

JAMA

1.Sevimli Dikicier B. KUTANÖZ SARKOİDOZ. GDD. 2018;3:33–43.

MLA

Sevimli Dikicier, Bahar. “KUTANÖZ SARKOİDOZ”. Güncel Dermatoloji Dergisi, vol. 3, no. 1, Apr. 2018, pp. 33-43, https://izlik.org/JA99BN93PN.

Vancouver

1.Bahar Sevimli Dikicier. KUTANÖZ SARKOİDOZ. GDD [Internet]. 2018 Apr. 1;3(1):33-4. Available from: https://izlik.org/JA99BN93PN